Prepared for intramuscular or subcutaneous injection using a freeze-drying method
An ampoule holds 1U (1mg of total proteins) of a dialyzed extract from humans’ leukocytes.
Ingredients : Low molecular weight dextran, potassium and sodium chloride, and a buffer of potassium and sodium phosphates.
It has been illustrated in leukocyte extracts that have been exposed to dialysis that various measures connected to the immune system, regardless if the antigen is specific or non-specific, are present. These include: delayed hypersensitivity transfer, and the enthusiasm of Leukocyte migration inhibition factor production.
The Lymphocyte Immune Factor (LIF) increases the production of Macrophage Migration Inhibitory Factor (MIF). This, in turn, leads to a greater number of lymphocytes which are stimulated by antigens, along with an increase in the size of cells which create rosettes with sheep erythrocytes.
The non-specific characteristics are extremely beneficial, like stimulating the transformation of lymphocytes with phytohemagglutin, inciting cytotoxic antibodies, and activating NK activities. An extract of dialyzed leukocytes also contains molecules with immunosuppressive and marrow-stimulating properties.
Signs:
For certain medical conditions, the use of Hebertrans is suggested.
Individuals with cellular immunological deficiency:
Testing of the skin for hypersensitivity, blasted transformation, LIF production, active and spontaneous rosettes, or quaintly lymphocytes in blood can all reveal immunodeficiency, which can be caused by bacterial, viral, mycosis and parasite infections, whether chronic or recurrent.
Hebertrans has been trialed in varying studies, both controlled and blind, on adults and children whose immune system has been weakened in the face of such issues as tonsillitis, respiratory tract infections which occur more or less often, severe sepsis in intensive care departments, including burns; urinary tract infections; keratomycosis; tuberculosis of the lungs and infections from herpes zoster and general herpes. In such cases, normalization or noteworthy improvement of cell immunity indicators was observed, as well as a therapeutic benefit for the patients.
The virus known as Herpes zoster is a common condition that affects many people. It is an infection that is caused by the same virus that is responsible for chickenpox. The infection can cause painful blisters on the skin that can take weeks to heal. It can also cause nerve pain that can last for months or even years. Treatment of Herpes zoster is important to reduce the symptoms and minimize the risk of spreading the virus.
The study demonstrated that the emergence of lesions and pain was decreased from 5.9 and 7.1 days to 5 days with a daily dosage of 1U Hebertrans. Furthermore, the side effects, like post herpes neuritis, were prevented in each case, and positive results were observed in isolated cases of eye herpes zoster.
The Herpes Virus
This virus, known as Herpes, is relatively common among humans. It is a contagious infection that is caused by either the HSV-1 or HSV-2 strain of the virus. It is spread through direct contact with an infected person, and it can cause cold sores and blisters. It is also possible to have the virus and have no symptoms. Treatment is available, but once infected, there is no cure.
In a pilot study involving patients with recurrent herpes in genital and other areas, the use of Hebertrans over a six-week period resulted in a reduction of the duration of outbreaks to 1-5 days, and also a decrease in relapse rates of 28% and 43% over the course of the one-year study. These results were supported by a controlled blind study. After eighteen weeks of treatment, there was a significant decrease in the frequency of relapses and the duration of lesions. After eighteen months, 67% of patients who had taken Hebertrans were completely cured, with the remaining 33% showing an improvement in their condition. When used in combination with antiviral therapy, Hebertrans was proven to be successful in reducing the time of healing of lesions and the number of relapses in children with mucous membrane herpes and cell immunodeficiency. Furthermore, it was seen to aid in the treatment of serious cases of herpes meningoencephalitis. In the case of herpes keratitis, the regular use of Hebertrans in a blind study was found to reduce the occurrence of complications like uveitis and corneal dystrophy (p≤0.008) and significantly reduce the amount of time it took for lesions to heal (p ≤0.002).
People suffering from cancer
In cases where neoplasia was detected, Hebertrans was administered with its catalysts if the patient’s immunity was deemed to be sufficient. Improvements could be observed in patients with sepsis, those that had undergone surgery and during the recovery from severe cases of leucopenia caused by leukostatics.
Conditions that involve allergies and the immune system
In an experimentally controlled case study of external bronchial asthma, the evidence of immune cells that were treated with Hebertrans over a period of 5 weeks and 1 year showed a reduction of 60% or decrease of 17% in the frequency of bronchial spasm crisis, and a normalization of 70% or a decrease of 12% in the value lgE, as well as a restoration to normal levels of 78% for the size of cells which produce active rosettes and a proved late hypersensitivity of skin. Regarding children with atopic dermatitis, the treatment of Hebertrans resulted in a clinical and laboratory improvement in 11 out of 12 cases in which the disease had weakened the cell’s immunity, however, it did not have any effect in 10 cases of normal cell resistance.
Patients with allergic kerato conjunctivitis showed positive responses to the application of Hebertrans.
Reasons for Not Using :
It is not advisable to administer Hebertrans to those who have an allergy to dextran or any of the salts used in the making of it.
Caution
It is essential to take heed of this warning.
It should be utilized immediately upon extraction from the pill, discarding any remaining matter. The pill is soluble in 1 ml of water for an injection and should be administered with care so as to avoid production of foam. Any changes in color or cloudiness indicate it should not be used.
Safety Measures
No studies have been conducted to determine the safety of using Hebertrans during pregnancy or lactation. Therefore, it is not recommended that it be used in these situations. A doctor should evaluate the potential risks of using it in each individual case before it is ingested.
In pediatrics, Hebertrans was administered to kids with main immunodeficiency and recurrent infections, specifically of the upper respiratory system, and infections caused by herpes. Despite the lengthy treatments, no significant side effects were noted, and no abnormalities in psychosomatic growth or development were observed.
Much debate surrounds the issue of
In only 2% of cases, a mild reddening of the skin where the injection was administered was observed; no major adverse effects were reported with the use of Hebertrans.
Involving other medicines and other forms of connections
No reports have been made.
Amounts
When treating adults, 1U is the usual dosage. For children, the dosage is typically calculated at 1-2U for each square meter of body surface.
The amount of medicine taken can depend on the medical condition and the progression of the illness: from one unit a day to seven days, and one to two units weekly; in certain cases of chronic diseases, the treatment may be prolonged up to half a year.
Storing Regulations
Preserve the item at temperatures ranging from 2-8° Celsius.
